Glenn Spehar

1.5k citations
8 papers · 1.2k indexed · 1 hit paper · h-index 7

Impact in

Papers in

    • Chronic Lymphocytic Leukemia Research 3
    • HER2/EGFR in Cancer Research 5

Glenn Spehar

7 papers receiving 1.1k citations

Hit Papers

Activity of the Dual Kinase Inhibitor Lapatinib (GW572016) against HER-2-Overexpressing and Trastuzumab-Treated Breast Cancer Cells 2006 · 711 citations
7112006202620122019200400600

Peers

Glenn Spehar
Comparison fields: 5 of 69
  • Oncology 806
  • Radiology, Nuclear Medicine and Imaging 340
  • Genetics 119
  • Cell Biology 132
  • Cancer Research 117
Replace Xuewu Zhang with:
Xuewu Zhang China
Edward Rosfjord United States
Jonathan Golas United States
Neil A. O’Brien United States
Careen K. Tang United States
Natalia Sergina United States
Peter Bross United States
Jonathan R. Reeves United Kingdom
Maria G. Olivares United States
Eugenia Kraynov United States
Glenn Spehar relative to Xuewu Zhang China Xuewu Zhang's profile →
Citations per field
00.5×1.5×
Xuewu Zhang · 1×
Citations per year

Countries citing papers authored by Glenn Spehar

Since Specialization
Citations

This map shows the geographic impact of Glenn Spehar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Glenn Spehar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Glenn Spehar more than expected).

Fields of papers citing papers by Glenn Spehar

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Glenn Spehar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Glenn Spehar. The network helps show where Glenn Spehar may publish in the future.

Co-authors

The 25 scholars most cited alongside Glenn Spehar, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Glenn Spehar Line = papers co-authored together Glenn Spehar links everyone, so they are left out of the graph.

All Works

8 of 8 papers shown
#Work
1 200933
2 200851
3 200872
4 200833
5 2007149
6 2007122
7 20070
8
Activity of the Dual Kinase Inhibitor Lapatinib (GW572016) against HER-2-Overexpressing and Trastuzumab-Treated Breast Cancer Cells
Hit paper breakdown →
2006711

About Glenn Spehar

Glenn Spehar is a scholar working on Genetics, Oncology, Pharmaceutical Science, Radiology, Nuclear Medicine and Imaging and Cell Biology, having authored 8 papers that have together received 1.2k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (5 papers), Chronic Lymphocytic Leukemia Research (3 papers), Monoclonal and Polyclonal Antibodies Research (3 papers), Microtubule and mitosis dynamics (2 papers), Ubiquitin and proteasome pathways (2 papers), Lung Cancer Treatments and Mutations (2 papers), Synthesis and biological activity (1 paper) and DNA Repair Mechanisms (1 paper). The work is most often cited by research in Oncology (806 citations), Radiology, Nuclear Medicine and Imaging (340 citations), Genetics (119 citations), Cell Biology (132 citations) and Cancer Research (117 citations). Glenn Spehar has collaborated with scholars based in United States, Netherlands and Japan. Frequent co-authors include Tona M. Gilmer, David W. Rusnak, Robert J. Mullin, Gottfried E. Konecny, Richard S. Finn, Guorong Yang, Barry R. Keith, Martina Rahmeh, Mark D. Pegram and Natarajan Venkatesan. Their work appears in journals such as Bioorganic & Medicinal Chemistry Letters, Cancer Research, Molecular Cancer Therapeutics, Journal of Clinical Oncology and Cell Proliferation.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026